Login / Signup

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants.

Kana FujimotoSatoru MutsuoYuto YasudaSoichi ArasawaNoriyuki TashimaDaisuke IwashimaKen-Ichi Takahashi
Published in: Infectious disease reports (2022)
Treatment with sotrovimab could prevent severe disease in high-risk patients infected with SARS-CoV-2 subvariant BA.5.
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • early onset
  • combination therapy
  • genome wide